INTRODUCTION
The central role of the vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR2) in vascular development during embryogenesis and in neovascularization of adult tissues have been well investigated. 1 However, emerging evidence indicates that VEGF also appears to be important in a variety of human pathological situations that are associated with aberrant endothelial proliferation and neovascularization, including atherosclerosis, sepsis, rheumatoid arthritis and other autoimmune diseases. 2 Angiogenesis is triggered by local signals such as the secretion of VEGF 3 and, among the VEGF family members, VEGF-A 165 , the main isoform of VEGF-A, 4 is a potent inducer of blood vessel growth: it is essential for vasculogenesis and angiogenesis during development 3, 5, 6 and has a significant impact on autoimmune diseases. 2 The pro-angiogenic signal emitted by VEGF-A/VEGFR2 stimulates preexisting endothelial cells and endothelial progenitors to proliferate and differentiate. 7 Angiogenesis is closely regulated by a balanced production of proand anti-angiogenic factors, including growth factors, cytokines, extracellular matrix molecules and metalloproteinases. 6 Metalloproteinases have attracted significant research interest because their inhibitors block angiogenesis in various in vitro and in vivo models. 5, 6 The metalloproteinase TACE (tumor necrosis factor a (TNF-a)-converting enzyme) has been shown to be of critical importance in angiogenesis, proposing that TACE is involved in pro-angiogenic pathways leading to vessel formation, promoting proliferation and differentiation of endothelial progenitor cells. [8] [9] [10] TACE is responsible for the release of the soluble form of TNF-a, and its production is closely linked to Sjö gren's syndrome (SS), an inflammatory autoimmune disorder that affects secretory organs such as the salivary and lacrimal glands [11] [12] [13] [14] but, a literature search yielded no data on the angiogenic role of TACE-dependent VEGF-A/VEGFR2 activation pathway in this disease. 15, 16 Based on these findings, in the current study we explore the involvement of TACE in VEGF/VEGFR-2-mediated angiogenesis in SS patients. As TNF-a is able to induce nuclear factor-kB (NF-kB) activation, 17 the study was additionally designed to determine the mechanism by which the anti-Ro/SSA autoantibodies (Abs) characterizing SS regulate VEGF-A/VEGFR2 expression through a TACE-dependent NF-kB activation pathway in an experimental model consisting of human salivary gland epithelial cells (SGEC) in culture.
RESULTS

SS Abs regulate VEGF-A/VEGFR2 system
To determine whether SS Abs induce mRNA changes in VEGF-A and VEGFR2 genes, we performed semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) and real-time PCR. Primary human SGEC cultures were treated with human antiRo/SSA Abs (50 mg ml À 1 ) for a period of 48 h. As shown in Figure 1a , following anti-Ro/SSA treatment, a clear upregulation of VEGF-A and VEGFR2 gene expression was observed. As depicted in Figure 1b , densitometric analysis, normalized against that of GAPDH, revealed that in anti-Ro/SSA Abs-treated cells the expression of VEGF-A was upregulated by about 3.2-fold, and VEGFR2 gene expression by about 2.2-fold in comparison with untreated control cells. The upregulation of each gene was statistically significant (Po0.01). We then quantified the mRNA levels by real-time PCR. Gene expression changes observed at realtime PCR are in agreement with the results monitored by semiquantitative RT-PCR (Figure 1c ), that showed a significant increase (Po0.01) of the mRNA expression of VEGF-A and VEGFR2 in anti-Ro/SSA Abs-treated cells (3.18 ± 1.2 and 2.19 ± 0.3 times, respectively) when compared with those in control/healthy IgG (HIgG)-treated SGEC. In the western blot analysis (Figures 2a  and b ) of VEGF-A, the band appeared at a little over 45 kDa. To investigate the anti-Ro/SSA-triggered molecular events that lead to the activation of VEGFR2, the phosphorylation level of this receptor was evaluated by western blotting using a phosphospecific antibody against Tyr 1214 within VEGFR-2. Figures 2a and b show that the anti-Ro/SSA Abs treatment induced VEGFR-2 phosphorylation on Tyr, 1214 allowing us to detect a band of 200 kDa. Concordantly, with the upregulation of VEGF-A and VEGFR2 mRNA levels in anti-Ro/SSA Abs-treated SGEC, a significant increase of the VEGF-A and VEGFR2 band intensity was also observed in comparison with untreated control SGEC and SGEC treated with HIgG. These results suggest that anti-Ro/SSA abs-treated healthy SGEC had an increased VEGF-A/VEGFR2 signaling. Flow cytometry images are shown in Figure 2c and results are largely in accordance to those of immunoblotting analysis. The expression of VEGF-A increased from 51.2% ± 1.6 in controls to 93.8% ± 1.53 (Po0.01) in treated SGEC. The expression of VEGFR2 followed a similar trend (33.37%±1.75 for untreated control SGEC versus 88.6%±1.37 for anti-Ro/SSA Abs-treated SGEC, Po0.01). We also assessed VEGF-A and VEGFR2 expression in SS patients, and found significantly higher gene and protein levels in comparison with healthy subjects (Figures 1 and 2 ). VEGF-Aand VEGFR2-specific cDNA amplification products were detected in all tissue specimens of healthy and SS labial salivary gland. The expression of VEGF-A and VEGFR2 genes was studied by semiquantitative RT-PCR and real-time PCR. As shown in Figures 1a-c, a clear upregulation of VEGF-A and VEGFR2 gene expression was observed in SS biopsies and densitometric analysis, normalized against that of GAPDH, revealed that the expression of VEGF-A and VEGFR2 increased remarkably in comparison with biopsied labial salivary glands from healthy controls. The upregulation of each gene was statistically significant (Po0.01). Western blot analysis (Figure 2a and b) provided comparable results to those of gene expression analysis, confirming that in SS tissues a significant increase of VEGF-A and phosphorylated VEGFR2 expression occurs in comparison with healthy labial salivary gland tissues. Flow cytometric analysis of protein expression also demonstrated that in SGEC derived from SS biopsies (Figure 2c ) there were high levels of VEGF-A expression (94.6%±1.7), similar to those observed in anti-Ro/SSA Abs-treated healthy SGEC. The expression of VEGFR2 followed a similar trend (88.6% ± 1.37 for anti-Ro/SSA Abs-treated healthy SGEC and 91.7%±1.37 for SS cells).
SS Abs stimulate an angiogenic response in the chorioallantoic membrane (CAM) The CAM assay, used to analyze the morpho-functional aspects of angiogenesis for its extensive vascularization and accessibility, was used to evaluate the pro-angiogenic activity of anti-Ro/SSA Abs treatment. At day 12 of incubation, a significant angiogenic response (420%) was induced by anti-Ro/SSA Abs treatment of Figure 1 . Increased VEGF-A and VEGFR2 gene expression in SS. mRNA levels of VEGF-A and VEGFR2 were quantified by semiquantitative RT-PCR (a, b) and real-time Taqman PCR (c). RT-PCR and real-time PCR were performed using specific primers and probes for VEGF-A and VEGFR2 on the total RNA isolated from human SGEC of healthy control subjects (C), HIgG-treated SGEC (HIgG), anti-Ro/SSA Abs-treated SGEC (anti-Ro) and SS biopsies (SS). In the RT-PCR analysis, the target genes were normalized to the average of the control gene GAPDH and expressed in arbitrary units. In the real-time PCR, b2-microglobulin normalized relative expression levels of VEGF-A and VEGFR2 mRNA are shown; f.i. ¼ fold induction. The data shown here are the average of three independent results. Asterisks indicate statistical significance as determined by Student's t-test (**Po0.01) of the difference in mRNA expression of VEGF-A and VEGFR2 in anti-Ro/SSA Abs-treated cells and SS SGEC in comparison with healthy control/HIgG-treated SGEC.
healthy SGEC in the form of numerous allantoic neovessels developing radially toward the implant in a 'spoked-wheel' pattern (mean number of vessels ¼ 22 ± 4 for SGEC culture medium and 28 ± 3 for culture medium of anti-Ro/SSA Abstreated SGEC; Figure 3 ). The angiogenic response induced by SS Abs (b) was comparable to that induced by VEGF-A (c) (mean number of vessels ¼ 27 ± 4). Culture medium, used as negative control, did not induce any angiogenic response (mean number of vessels ¼ 7±1) (a).
Immunohistochemical staining of VEGF-A and VEGFR2 in anti-Ro/SSA Abs-treated SGEC correlated with clinicopathological parameters observed in SS We performed immunohistochemistry of SGEC cultures to examine the effect of anti-Ro/SSA Abs treatment on VEGF-A and VEGFR2 expression in comparison with untreated healthy SGEC. In anti-Ro/SSA Abs-treated SGEC, a significant increase of VEGF-A and VEGFR2 staining intensity was observed in comparison with untreated control SGEC and SGEC treated with HIgG ( Figure 4A ). To complement studies performed on anti-Ro/SSA-treated cultured SGEC, we examined the expression of VEGF-A and VEGFR2 in the salivary glands of patients with SS. Diffuse infiltrating mononuclear cells were found in the salivary glands of SS biopsies around the blood vessels ( Figure 4B ). We found a strongly positive staining for VEGF-A and VEGFR2 proteins in the biopsy specimens from SS patients examined in the immunohistochemical study. VEGF-A was immunolocalized in the cytoplasm of acinar cells, epithelial cells of both striated and intercalated ducts, as well as in endothelial cells of blood capillaries or venules ( Figure 4B(c) ). VEGFR2 was localized on the cell membrane but also widespread in the cytoplasm of both acinar and ductal cells ( Figure 4B(f) ). In normal salivary gland tissues, a weak VEGF-A and VEGFR2 expression was revealed with the same localization observed in SS subjects. Our findings clearly demonstrate changes in the levels of protein expression between healthy controls and SS patients salivary gland biopsies. 
TACE is involved in VEGF-A-dependent angiogenesis induced by SS Abs
Given the importance of TACE as an important regulator of several key steps during angiogenesis, 18 we assessed the role of TACE in the pathological neovascularization induced by SS Abs. In anti-Ro/ SSA Abs-treated SGEC, we inhibited VEGF-A expression through the use of a specific anti-human VEGF-A monoclonal antibody (mAb). As showed by immunoblotting analysis, the blocking anti-VEGF-A antibody determined the disappearance of the active processed form of TACE lacking the pro-domain. The addition of exogenous VEGF-A restored the shedding and activation of TACE (Figure 5a) .
To test the possibility that TACE is involved in VEGF-A-induced VEGFR2 upregulation in anti-Ro/SSA Abs-treated healthy SGEC, we used the siRNA-mediated gene-silencing technique (Figure 5b ). We used siRNA to knock down the expression of TACE and evaluate the effects on VEGFR2 expression. Flow cytometric analysis demonstrated that TACE gene silencing caused a reduction of VEGFR2 expression in anti-Ro/SSA Abs-treated healthy SGEC. Blocking VEGF-A in anti-Ro/SSA Abs-treated healthy SGEC had similar effects to those obtained by TACE gene silencing (Figure 5b ). The finding that the upregulation of the anti-Ro/SSA Abs/VEGF-A-induced VEGFR2 expression was inhibited by TACE gene silencing, as well as by blocking VEGF-A expression, lends strong support to the hypothesis that SS Abs exert their pro-angiogenic effect through the activation of TACE.
Anti-Ro/SSA Abs-induced NF-kB activity was correlated with VEGF-A expression Recent studies have shown that the secretion of angiogenic factors may be an important mechanism of constitutive NF-kB activation observed in pathological conditions. 19 Here we evaluated (i) whether the anti-Ro/SSA Abs-induced VEGF-A production is directly involved in the regulation of constitutive NF-kB signaling and (ii) whether blocking the anti-Ro/SSA Abs-induced VEGF-A production by a anti-human VEGF-A mAb affects NF-kB nuclear translocation. Data presented here show that increased VEGF-A expression was correlated with nuclear NFkB translocation when human SGEC were stimulated with anti-Ro/ SSA Abs ( Figure 6 ). Enzyme-linked immunosorbent assay (ELISA) NFkB p65 analysis demonstrated 3.07-fold more DNA binding by p65 in the nuclear extracts derived from anti-Ro/SSA Abs-treated SGEC as compared with untreated control SGEC. When anti-Ro/ SSA Abs-induced VEGF-A was specifically blocked, a remarkable decrease of NF-kB activation was observed (2.24±0.031 in the nuclear extracts derived from anti-Ro/SSA Abs-treated SGEC versus 1.15 ± 0.043 in the nuclear extracts from anti-Ro/SSA Abs plus anti-human VEGF-A mAb-treated SGEC). Following the addition of exogenous VEGF-A, we found that the constitutive NF-kB binding activity was restored (from 1.15±0.043 in the nuclear extracts from anti-Ro/SSA Abs plus anti-human VEGF-A mAb-treated SGEC to 2.13 ± 0.025 in the nuclear extracts from exogenous VEGF-A-treated SGEC).
Pro-angiogenic chemokines/cytokines secretion was induced by anti-Ro/SSA Abs-mediated NF-kB activation To investigate the pro-angiogenic target genes of NF-kB activation in anti-Ro/SSA-treated human SGEC, transcription profiles were determined by human cytokines array analysis. Human cytokines array analysis revealed that, following anti-Ro/SSA Abs treatment a large number of pro-angiogenic factors were upregulated as compared with untreated control SGEC. Of the 34 genes that are characterized as positive regulators of angiogenesis, several showed a 42-fold increase in expression. The levels of GROa (growth-related oncogene-a), interleukin (IL)-1a, IL-6, IL-8, IL-13, IL-17, MIF-1a (macrophage inhibitory factor-1a), RANTES (regulated upon activation, normal T-cell expressed, and secreted) and TNF-a expression were increased, whereas Serpin (serine protease inhibitors) expression was unchanged. Furthermore, the secretion of pro-angiogenic chemokines/cytokines was markedly suppressed by anti-human VEGF-A antibody (Figure 7) . These results suggest that human SGEC activated with anti-Ro/SSA Abs secrete pro-inflammatory and pro-angiogenic factors. Densitometric analysis of these data confirmed a significant enrichment of the expected pro-angiogenic and pro-inflammatory target genes.
Blocking the VEGF-A/TACE/NF-kB pathway decreases anti-Ro/SSA Abs-induced pro-angiogenic factors expression To confirm the induction of pro-angiogenic factors by anti-Ro/SSA Abs treatment of human SGEC through the activation of a pathway involving VEGF-A, TACE, VEGFR2 and NF-kB, the effect of TACE gene knockdown (Figure 7d ) and NF-kB inactivation by a dominant negative IkBa vector (Figure 7e ) were examined in anti-Ro/SSA Abs-treated healthy SGEC (Figure 7) . We used the dominant negative super-repressor inhibitory protein IkBa Figure 7 . A typical pattern of the membrane protein array for detecting chemokines/ cytokines and angiogenic factors (spots relevant to this study are in a circle). Human cytokine array analysis of the protein response in anti-Ro/SSA abs-treated human SGEC (b) revealed that a large number of pro-angiogenic factors were upregulated as compared with untreated control SGEC (a).The levels of GROa, IL-1a, IL-6, IL-8, IL-13, IL-17, MIF-1a, RANTES and TNF-a expression increased. SGEC treatment with anti-human VEGF-A antibody (c) suppressed the secretion of proangiogenic chemokines/cytokines. Results from the protein array demonstrated that the pro-angiogenic factors expression induced by Abs treatment was significantly decreased after TACE gene silencing (d) and NF-kB nuclear translocation inhibition by IkBaDN (e). Densitometric analysis confirmed these results (f ). Array analysis suggests that inhibition of VEGFR2 activation by TACE gene silencing and removal of the feedback regulation of NF-kB by IkBaDN reduced NF-kB activation, which sequentially altered the expression of pro-angiogenic target genes. Asterisks indicate that the pro-angiogenic factors expression induced by Abs treatment was significantly (**Po0.01) decreased after TACE gene silencing and NF-kB nuclear translocation inhibition by IkBaDN.
(IkBaDN) that contains mutations at residues 32 and 36, which disrupt phosphorylation and subsequent degradation, as the NF-kB-DNA binding inhibitor. As expected, the results from the protein array demonstrated that the pro-angiogenic factors expression induced by Abs treatment was significantly (Po0.01) decreased after TACE gene silencing (Figure 7d ) and NF-kB nuclear translocation inhibition by IkBaDN (Figure 7e ). This array analysis suggests that inhibition of VEGFR2 activation by TACE gene silencing and the removal of the feedback regulation of NF-kB by IkBaDN sequentially altered the expression of pro-angiogenic target genes, suggesting one possible mechanism for TACE-mediated angiogenesis that involves NF-kB nuclear translocation. DISCUSSION VEGF-A was originally described as a specific angiogenic and permeability-inducing factor, and its function was considered to be specific for endothelial cells. However, emerging evidence has revealed that the role of the VEGF-A/VEGFR2 system extends far beyond previous expectations. This system has been shown to have multiple functions, such as the induction of tumor metastasis, inflammation, neuroprotection, as well as lymphangiogenesis. 20 In autoimmune diseases, VEGF-A functions as a proinflammatory cytokine by increasing the permeability of endothelial cells and inducing the expression of endothelial adhesion molecules. 20, 21 There is considerable evidence of an interrelationship between the VEGF-A/VEGFR2 system and various autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. 2 This study extends the list of VEGF-A/VEGFR2-dependent autoimmune disease conditions, providing new insight into a potential angiogenesis-related signaling pathway triggered by anti-Ro/SSA Abs in SS. We provide the first observation of a relation between VEGF-A production, VEGFR2 activation and SS Abs, demonstrating that anti-Ro/SSA Abs increased VEGF-A expression and triggered upregulation and activation of VEGFR2. Observations made in salivary gland biopsies from SS patients confirmed that, in chronically inflamed glands, considerable amounts of VEGF-A were found in both glandular epithelium and inflammatory cells. The angiogenic effects of VEGF-A may be responsible for the increased number of blood vessels observed in SS salivary glands. 22, 23 The enhanced angiogenesis was associated with an increased VEGF-A/VEGFR2 signaling, as demonstrated by the observation of an increased amount of phosphorylated VEGFR2 in SS salivary glands biopsies. Given the critical role of VEGFR2 signaling in angiogenesis, antiRo/SSA Abs-regulated VEGFR2 activation may represent an important mechanism in the control of angiogenesis in SS. In addition, the pro-angiogenic activity of SS Abs was demonstrated by the CAM assay, used to analyze the morpho-functional aspects of angiogenesis for its extensive vascularization and accessibility. 24 The results of the present study, showing actively induced neovascularization on the CAM, provide direct evidence that anti-Ro/SSA Abs have angiogenic potential.
Recent findings identify TACE as an important regulator of several key steps during angiogenesis. 10, 25 Our previous experimental data demonstrated that human SGEC express TACE that is activated following anti-Ro/SSA Abs treatment. 26 Here we found that TACE has a role in the pathological neovascularization induced by anti-Ro/SSA Abs; in fact, by blocking VEGF-A we demonstrated that TACE shedding and activation occurs through VEGF-A. In addition, TACE expression knockdown using the siRNA gene-silencing technique had an evident effect on developmental angiogenesis, demonstrating that TACE determined changes in human VEGFR2 expression and regulated phosphorylation of this receptor, providing the evidence that SS Abs exert their pro-angiogenic effect through the activation of TACE.
VEGF-A can be regulated by activated NF-kB, because its genes have a kB binding site in its promoter region 27 and the secretion of angiogenic factors may be an important mechanism of constitutive NF-kB activation observed in pathological conditions. 19 A correlation between VEGF-A expression and NF-kB activation is well documented in the literature and recent studies have shown that activated NF-kB has a key role in malignant neoplastic angiogenesis. 19, 28, 29 To the best of our knowledge, there are no reports on the relationship between NF-kB nuclear localization, VEGF-A/VEGFR2 aberrant expression and autoimmune diseases. Our previous study demonstrated a higher transcriptional activity of NF-kB in SS than in normal subjects, suggesting that the NF-kB signal is important for modulating immune responses in human SGEC in this autoimmune condition. 30 Here we demonstrated that in anti-Ro/ SSA Abs-treated human SGEC increased VEGF-A expression was correlated with nuclear NF-kB translocation. The use of anti-VEGF-A mAb blocked the anti-Ro/SSA Abs-induced VEGF-A molecules and thus determined a remarkable decrease of NF-kB activation, whereas treatment with exogenous VEGF-A reversed the effect of VEGF-A neutralization. These data corroborate the hypothesis that the NF-kB signaling pathway is directly involved in the regulation of SS Abs-induced VEGF-A/VEGFR2 expression in human SGEC.
Accumulating evidence suggests a major integration and codependence of inflammation with the processes of pathological angiogenesis. However, the underlying signaling mechanism initiating and promoting the coordinate regulation of angiogenesis and inflammation remains an open question. Pro-inflammatory cytokines may exert direct angiogenic activity or may function indirectly via VEGF-dependent pathways. 31 Therefore, we investigated the pro-angiogenic target genes expression showing that the secretion of pro-angiogenic factors could depend on anti-Ro/SSA-mediated NF-kB activation. Human cytokines array analysis of the pro-inflammatory and proangiogenic protein response in human SGEC treated with SS Abs revealed a large number of upregulated pro-inflammatory and pro-angiogenic factors, blocked by treatment of the cells with anti-human VEGF-A antibody. The use of TACE siRNA demonstrated that TACE is able to trigger anti-Ro/SSA Absdependent NF-kB activation and downstream events that lead to pro-angiogenic factor release. To further investigate the role of NF-kB activity in anti-Ro/SSA Abs-mediated angiogenesis, we inhibited NF-kB activity by introducing stable expression of a phosphorylation-defective IkBa mutant. Ectopic expression of IkBaDN effectively abolished Abs-induced pro-angiogenic factors production, blocking the transcription of genes needed for new endothelial cells growth.
In summary, we report substantial evidence indicating that, in SS, the production of pro-angiogenic factors from human salivary glands epithelial cells occurs via the VEGF-A/TACE/VEGFR2/NF-kB axis activation suggesting novel anti-angiogenic strategies that could result in discovery of more selective therapeutic options. Notwithstanding the current knowledge regarding new blood vessel formation pathways, in the research setting, continued understanding of endothelial cells function improves insight into vasculogenesis and the pathology of vascular dysfunction in autoimmune diseases. Data presented in this paper can then be exploited to design intervention at various stages of autoimmune diseases and to provide new therapies that not only mitigate the symptoms of these diseases but may also facilitate regeneration of organ function.
MATERIALS AND METHODS
Study subjects
Thirteen patients with SS (10 women, 3 men; mean age, 58 years; age range, 46-70 years) were recruited from the Rheumatology Clinic. Patients were included if they had received a diagnosis of SS according to the 32 Patients who underwent salivary glands biopsies did not receive any pharmacological treatment. Healthy volunteers (7 women, 3 men; mean age, 54 years; age range, 42-66 years) with no salivary condition were included. Informed consent was obtained for all subjects recruited to this experimental study. Labial minor glands were harvested from the lower lip as previously reported. 33 Microdissection and primary explant cultures of human SGEC Healthy and SS salivary gland-derived epithelial cells were isolated from limited amounts of human salivary glandular tissue and cultured in McCoy's 5a modified medium supplemented with 10% fetal bovine serum, 1% antibiotic solution, 2 mM L-glutamine, 20 ng ml À 1 epidermal growth factor (EGF, Promega, Madison, WI, USA), 0.5 mg ml À 1 insulin (Novo, Bagsvaerd, Denmark) and incubated at 37 1C, 5% CO 2 in air. Ethylene diamine tetraacetic acid (EDTA) 0.02% was used to selectively remove contaminating fibroblasts. The epithelial origin of cells within confluent monolayers was confirmed by examining epithelial-specific markers. 34 A portion of healthy and SS salivary glands obtained at surgery was used to extract RNA and proteins and for morphological and immunohistochemical experiments.
Autoantibodies
Anti-Ro/SSA Abs were purified from IgG fractions of patients with primary SS (n ¼ 33; mean age 46.5 years) as previously reported. 35, 36 Cell treatment SGEC were collected and resuspended at 1 Â 10 6 cells per ml in McCoy's 5a modified medium. Cells were treated as follows: (1) Semiquantitative RT-PCR and real-time PCR Total RNA was extracted, reverse transcribed and cDNA preparation was used for each PCR as previously described. 36 After initial denaturation at 94 1C for 5 min, 35 cycles were performed (denaturation at 94 1C for 30 s, annealing at 62 1C for 30 s and 60 1C for 30 s (for VEGF-A and VEGFR2, respectively) and extension at 72 1C for 1 min) followed by 10 min at 72 1C. Equal amounts of PCR products were run on a 1.5% agarose gel containing ethidium bromide. The PCR primers were designed according to published sequences (ref. source: www.ncbi.nlm.nih.gov) and reported in Table 1 . Densitometric analysis was performed by gel image software (Bio-Profil Bio-1D; ltf Labortechnik GmbH, Wasserburg, Germany) to quantify mRNA expression levels relative to GAPDH (internal control for lane loading). The identity of each PCR product was confirmed by sequencing. For real-time PCR, TaqMan expression assays, including fluorescent probes, forward and reverse primers (Assays-On-Demand, Applied Biosystems, Foster City, CA, USA) and the internal control gene b-2 microglobulin (part no. 4326319E; b2M) were purchased from Applied Biosystems. Real-time quantitative PCR was performed with an ABI PRISM 7700 (Applied Biosystems). The threshold was determined as 10 times the s.d. of the baseline fluorescence signal. The cycle number at the threshold was used as the threshold cycle. The probes used are reported in Table 1. Western blot Protein lysates, obtained from variously treated healthy SGEC, untreated control SGEC and SS cells, were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Membranes were incubated for 90 min with mouse anti-human VEGF-A mAb, rabbit anti-human VEGFR2 phosphorylated polyclonal antibody, goat anti-human TACE polyclonal antibody (all from Santa Cruz Biotechnology) and with the relative secondary antibodies-HRP (horseradish peroxidase) conjugates (Santa Cruz Biotechnology). Proteins recognized by the antibodies were revealed using the chemiluminescence luminal reagent (Santa Cruz Biotechnology) according to the protocol. b-Actin was used as protein loading control.
Flow cytometry
For flow cytometric analysis, SS and variously treated healthy SCEC were incubated with anti-human TACE-phycoerythrin mAb, anti-human VEGF-Aphycoerythrin mAb and anti-human VEGFR2-phycoerythrin mAb (all from R&D Systems). 
Chicken embryonic CAM angiogenesis assay
Fertilized White Leghorn chicken eggs (30 per group) were incubated at 37 1C at constant humidity. On day 3, a square window was opened in the shell, and 2-3 ml of albumin was removed to allow detachment of the developing CAM. The window was sealed with a glass, and the eggs were returned to the incubator. On day 8, eggs were treated with 1 mm 3 sterilized gelatin sponges (Gelfoam, Pharmacia & Upjohn Co., Kalamazoo, MI, USA) placed on top of the growing CAM, as previously described 24 and loaded with: 1 ml of culture medium as negative control; 1 ml culture medium containing 200 ng of recombinant VEGF-A (R&D Systems) as positive control; 1 ml of SGEC culture medium; 1 ml of culture medium of SGEC treated with anti-Ro/SSA Abs. CAMs were examined daily until day 12 and photographed in ovo with a stereomicroscope equipped with a camera and image analyzer system (Olympus Italia, Milan, Italy). At day 12 the angiogenic response was evaluated by the image analyzer system as the number of vessels converging toward the sponge.
Immunohistochemistry
In the cell immunohistochemistry assay, an anti-human VEGF-A and an anti-human VEGFR2 antibodies (Santa Cruz Biotechnology) were used as primary antibodies and an HRP-conjugated secondary antibody (Santa Cruz Biotechnology) was added. The slides were incubated with diamino benzidine tetrahydrochloride (DAB) (Sigma, St Louis, MO, USA) as substrate. For the immunohistochemical analysis of paraffin-embedded human salivary gland tissues, 3-mm serial sections of healthy and SS formalin-fixed, paraffin-embedded tissue were used. After incubation with the primary antibodies against VEGF-A and VEGFR2 (SABiosciences, Frederick, MD, USA), the slides were incubated with the HRP-conjugated secondary antibody (Santa Cruz Biotechnology). Afterwards the slides were incubated with DAB (Sigma) as substrate and counterstained with hematoxylin (Merck Eurolab, Dietikon, Switzerland). Negative controls without primary antibody were included in each experiment to verify antibody specificity. The images were captured under a light microscope. Reverse (5'-3') Probe (5'-FAM and 3'-TAMRA labeled)
Abbreviations: b2M, b-2 microglobulin; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2.
NF-kB DNA binding assays Preparation of nuclear extract of variously treated healthy cells was performed as per the instructions given in the Trans AM Flexi kit (Active Motif, Carlsbad, CA, USA). The NF-kB activity was estimated by ELISA. All the tests were performed in duplicate. To each well containing a NF-kB consensus binding site (5'-GGGACTTTCC-3'), 10 mg of nuclear extract was added. We used nuclear extract of Raji cells (a Burkitt's lymphoma cell line) as positive control (Active Motif). The absorbance was measured at 450 nm by the VERSAmax microplate reader (Molecular Devices Corp, Silicon Valley, CA, USA).
Pro-angiogenic chemokines/cytokines array
The human cytokine array (Proteome Profiler Array Human Cytokine, R&D Systems) was used to simultaneously detect the relative levels of 36 different cytokines, chemokines and pro-angiogenic factors. The array was performed according to the manufacturer's instructions. Levels of proteins were visualized by chemiluminescence and within a linear range of exposure quantified by Quantity One software (Bio-Rad, Hercules, CA, USA). The protein levels on each array were standardized against an internal positive control on the array. The pro-angiogenic and pro-inflammatory factors tested are listed in Supplementary Table. Inhibitors TACE gene silencing. Transfection of 21-nucleotide siRNA duplexes (Ambion, Austin, TX, USA) was done for TACE silencing in healthy SGEC. Briefly, SGEC were transfected with siRNA using the siPORT NeoFX transfection agent (Ambion). The highest efficiencies in silencing target genes were obtained by using mixtures of siRNA duplexes targeting different regions of the genes of interest. A positive control using GAPDH siRNA (Ambion) and a negative control with no known sequence similarity to human genes were included. Silencing was observed by mRNA quantification.
Transient transfection with the dominant negative version of IkBa and luciferase assay. For transient transfections, 2 Â 10 5 healthy SGEC were seeded per well in a 24-well tissue culture dish. Cells were transfected using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) with 10 mg ml À 1 of the dominant negative inhibitory kBa protein (IkBa) vector (IkBaDN) and a plasmid DNA, including a NF-kB luciferase reporter construct or the empty vector (pCMV, Clontech, San Diego, CA, USA), according to the manufacturer's instructions. The IkBaDN, containing mutations at residues 32 and 36 (the two inducible phosphorylation sites), which disrupt phosphorylation and subsequent degradation, was a kind gift from Dr P Bauerle, University of Munich and Dr M Lienhard Schmitz, Deutsches Krebsforschungszentrum, Germany; the NF-kB luciferase vector contains four tandem copies of the NF-kB consensus sequence fused to a TATA-like promoter region from the herpes simplex virus thymidine kinase promoter. Luciferase activity was measured by the Luciferase Reporter Assay System (Promega) and normalized to b-galactosidase activity as internal control.
Statistics
The data were analyzed for normality using the Wilks Shapiro test. Differences in means for paired observations were analyzed by Student's t-test. In all instances values of Po0.05 were considered statistically significant.
